Kyongbo Pharmaceutical Valuation

Is A214390 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A214390 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A214390's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A214390's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A214390?

Key metric: As A214390 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A214390. This is calculated by dividing A214390's market cap by their current earnings.
What is A214390's PE Ratio?
PE Ratio	33.2x
Earnings	₩5.36b
Market Cap	₩177.87b

A214390 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	11.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A214390's PE Ratio compare to its peers?

The above table shows the PE ratio for A214390 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.5x
A234080 JW Lifescience	6.8x	n/a	₩180.7b
A032300 KOREA PHARMA	58.3x	n/a	₩174.5b
A000020 Dongwha Pharm.Co.Ltd	23.8x	n/a	₩182.9b
A023910 Daihan PharmaceuticalLtd	5x	0.9%	₩154.1b
A214390 Kyongbo Pharmaceutical	33.2x	n/a	₩177.9b

Price-To-Earnings vs Peers: A214390 is good value based on its Price-To-Earnings Ratio (33.2x) compared to the peer average (43.5x).

Price to Earnings Ratio vs Industry

How does A214390's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A007370 Jin Yang Pharmaceutical	2.4x	n/a	US$47.51m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A214390 is expensive based on its Price-To-Earnings Ratio (33.2x) compared to the KR Pharmaceuticals industry average (13.5x).

Price to Earnings Ratio vs Fair Ratio

What is A214390's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A214390 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	33.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A214390's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩271,000.00

-1.8%

76.5%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

-4.8%

n/a

Dong-A ST

₩554.0b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩61,700.00

-9.7%

7.9%